OMNARIS

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Hong Kong SAR China, Mexico, New Zealand, Singapore.

Active ingredients

The drug OMNARIS contains one active pharmaceutical ingredient (API):

1	Ciclesonide UNII S59502J185 - CICLESONIDE
	Ciclesonide exhibits low binding affinity to the glucocorticoid-receptor. Once orally inhaled, ciclesonide is enzymatically converted in the lungs to the principal metabolite (C21-des-methylpropionyl-ciclesonide) which has a pronounced anti-inflammatory activity and is thus considered as the active metabolite.
	Read more about Ciclesonide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OMNARIS Nasal spray	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R01AD13		R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501104701171319, 562620040000617
CA	Health Products and Food Branch	02303671
HK	Department of Health Drug Office	59322
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	128M2009
NZ	Medicines and Medical Devices Safety Authority	14526
SG	Health Sciences Authority	13911P
US	FDA, National Drug Code	70515-701